Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 47,000
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
141% more first-time investments, than exits
New positions opened: 475 | Existing positions closed: 197
6% more funds holding
Funds holding: 3,609 [Q3] → 3,814 (+205) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 1,507 | Existing positions reduced: 1,448
0.13% more ownership
Funds ownership: 81.81% [Q3] → 81.94% (+0.13%) [Q4]
9% less call options, than puts
Call options by funds: $9.28B | Put options by funds: $10.1B
11% less capital invested
Capital invested by funds: $676B [Q3] → $604B (-$72.3B) [Q4]
30% less funds holding in top 10
Funds holding in top 10: 464 [Q3] → 325 (-139) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$888
6%
upside
Avg. target
$1,045
24%
upside
High target
$1,190
42%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Seamus Fernandez 38% 1-year accuracy 8 / 21 met price target | 10%upside $928 | Buy Maintained | 14 Apr 2025 |
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target | 34%upside $1,124 | Overweight Maintained | 9 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 6%upside $888 | Buy Upgraded | 8 Apr 2025 |
Wells Fargo Mohit Bansal 26% 1-year accuracy 7 / 27 met price target | 31%upside $1,100 | Overweight Maintained | 5 Mar 2025 |
Truist Securities Srikripa Devarakonda 16% 1-year accuracy 5 / 31 met price target | 24%upside $1,038 | Buy Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 134 articles about LLY published over the past 30 days
Neutral
Seeking Alpha
4 hours ago
Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging
Eli Lilly's recent Phase III results for its oral weight loss pill have demonstrated remarkable results. LLY has emerged as the frontrunner to tap into the next stage of growth through Orforglipron, potentially surpassing Novo Nordisk. Lilly's domestic capacity could provide it an edge against Denmark-based NVO, although supply chain risks imputed to tariffs cannot be downplayed.
Neutral
The Motley Fool
7 hours ago
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first of several phase 3 drug trials.
Negative
The Motley Fool
21 hours ago
Is Eli Lilly Stock a Buy Right Now?
One of the more interesting aspects about President Donald Trump's recent tariffs is that each major industry has shown at least some degree of weakness, regardless of whether the policies have directly affected them yet.
Positive
The Motley Fool
1 day ago
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that sales of anti-obesity drugs could soar.
Neutral
WSJ
1 day ago
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news
Positive
Barrons
2 days ago
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing
Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.
Positive
24/7 Wall Street
2 days ago
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Neutral
The Motley Fool
2 days ago
Where Will Eli Lilly Be in 5 Years?
What a difference five years can make. Just look at Eli Lilly (LLY 14.56%).
Positive
CNBC Television
2 days ago
Eli Lilly jumps on GLP-1 pill trial success
CNBC's Angelica Peebles joins 'Fast Money' to talk the latest on oral GLP-1 trials.
Positive
Yahoo Finance
2 days ago
Eli Lilly's weight-loss pill: What it means for the sector
Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton, Unlimited co-founder, CEO, and chief investment officer Bob Elliott, and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to explain why the test results sent the pharmaceutical stock soaring.
Charts implemented using Lightweight Charts™